Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

ny dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's website at http://www.exelixis.com.

Disclaimer

Participation by Dr. Ball and Dr. Nelkin in the development of this product as members of the Clinical Steering Committee does not constitute endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to: the timing of the initiation and size of clinical trials for XL184; the future development and potential efficacy of XL184; and our strategy to advance compounds and expand into broader commercial markets. Words such as "plan," "expect," "will," "may" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL184 and our other compounds to demonstrate safety and efficacy in clinical
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ... 29, 2015 , ... The global microfluidics market is expected ... (2015 to 2020). The market is mainly driven by the rising geriatric population, ... However, lack of adequate healthcare and research infrastructure in emerging markets, dearth of ...
(Date:6/29/2015)... 2015  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical ... molecule and cell therapy treatments for central nervous system ... listing on the NASDAQ Capital Market under the symbol ... on the NYSE MKT until the market close on ... is expected to commence on July 13, 2015. ...
(Date:6/29/2015)...   For the seventh year running, Across Health conducted ... digital maturity called the Multichannel Maturometer . The ... maturing fast enough. While it,s true that technology is ... and customers are increasingly "digital natives", pharma still lags ... ...
(Date:6/26/2015)... , June 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced that all nominees listed in the management ... at its 2015 Annual Meeting of Shareholders, held ... by ballot, the following 5 nominees proposed by ... to serve until the Company,s next Annual Meeting ...
Breaking Biology Technology:Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3
... Group, Inc.,released its third annual TreatmentTrends(TM): The Use ... the management of,Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), ... responses to an online survey,completed by 100 US ... study, the majority of Rheumatologists reported an,increase in ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... scheduled to participate in the upcoming UBS Global Life,Sciences ... York City., D. Ashley Lee, executive vice president, ... will present Wednesday,September 24 at 2:30 p.m., Eastern Time., ...
... Conn., Sept. 17 MannKind Corporation,(Nasdaq: MNKD ) ... States,Food and Drug Administration to use AFRESA as the ... uh-FRESS-uh) was unveiled today by Alfred Mann,Chairman and Chief ... Danbury, Conn., location that marked the completion and,dedication of ...
Cached Biology Technology:Use of Biologic Agents Continues to Expand Among US Rheumatologists - Can New Agents Shift the Treatment Paradigm in Rheumatoid Arthritis? 2CryoLife to Present at UBS Global Life Sciences Conference 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 2MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility 3
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
(Date:6/9/2015)... Minn. , June 9, 2015   MedNet ... supports the entire spectrum of clinical research, will be ... eClinical technology platform at the 2015 Drug Information Association ... on June 15-17.  These presentations will include previews ... rolled out in the upcoming iMedNet 2015 ...
(Date:6/8/2015)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer of cell-free ... Cancer Monitoring SM platform will be presented at the ... San Diego, CA on June 11-12 , ... Genomics and Cancer Therapy in Salt Lake ... "We continue to advance our clinical programs and present data ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... Ariz. A group of researchers from Arizona State University ... in the study of human proteins that could open up ... work is being reported in this week,s Science ... G-protein-coupled receptors," the team reports that they have been successful ...
... forests, a Michigan State University (MSU) sustainability scholar proposes a ... fall in China, can you hear it elsewhere in the ... Pacific Policy Studies , MSU,s University Distinguished Professor Jianguo "Jack" ... and expand its forests even as its cities and population ...
... presence of male sperm and seminal fluid causes female worms to ... week in the journal Science . The demise of the ... the mating pool for other males. The researchers found ... to dehydrate, prematurely age and die. "Their lifespans are ...
Cached Biology News:ASU researchers develop new device to help image key proteins at room temperature 2ASU researchers develop new device to help image key proteins at room temperature 3Telecoupling science shows China's forest sustainability packs global impact 2Mating is the kiss of death for certain female worms 2Mating is the kiss of death for certain female worms 3
... Sigma-Genosys offers custom peptide synthesis with a wide ... best fit your research needs. Purity: ... Yield: 2mg-1g Sequence Length: ... Biotin, Fluorescein, N-acetylation, C-amidation, phosphorylation, D-amino acids, MAPs, ...
... liquid handling system from Molecular Devices provides ... one instrument. The system handles a variety ... washing96-, 384- and 1536-welland is the first ... has been optimized to dispense from four ...
A univariate (peak height or area) quantitative multi-component analysis package....
... micro 1 is a dramatic breakthrough in accurate, ... with 10nL resolution, the micro 1 has unique ... And, the micro 1 never needs re-calibration as ... Screen programming on an LCD Display , Graphical ...
Biology Products: